Monotherapy of exudative age-related macular degeneration with ranibizumab in patients at cardiovascular risk: Advantages of ranibizumab compared to a combination with pegaptanib;Monotherapie der exsudativen altersbedingten Makuladegeneration bei kardiovaskulären Risikopatienten: Vorteile für Ranibizumab gegenüber einer Kombination mit Pegaptanib

Ophthalmologe

Volumn 108, Issue 4, 2011, Pages 337-341

  Matthe E ^a   Sandner, D ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Age related macular degeneration; Cardiovascular risk; Combination therapy; Pegaptanib; Ranibizumab

Indexed keywords

APTAMER; MONOCLONAL ANTIBODY; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ARTICLE; COMPARATIVE STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; EXUDATIVE MACULAR DEGENERATION; FEMALE; HEART INFARCTION; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; MALE; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; STENT; STROKE; SUBRETINAL NEOVASCULARIZATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; CHOROIDAL NEOVASCULARIZATION; CORONARY ARTERY BYPASS; CORONARY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; RISK FACTORS; STENTS; STROKE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 79955479134     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-010-2300-y     Document Type: Article

References (14)

1. Ambati J, Ambati BK, Yoo SH et al (2003) Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 48(3): 257-293.
2. Bartz-Schmidt KU, Ziemssen F (2008) Intravitreale Pharmakotherapie. Schattauer, Stuttgart New York.
3. Boyer DS, Antoszyk AN, Awh CC et al (2007) Subgroup Analysis of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular Degeneration. Ophthalmology 114(2): 246-252.
4. Chia EM, Wang JJ, Rochtchina E et al (2004) Impact of bilateral visual impairment on health-related quality of life: the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci 45: 71-76.
5. Eter N (2009) Die altersabhängige Makuladegeneration. Uni-med Bremen.
6. Heier JS, Shapiro H, Singh AA (2006) Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age-related macular degeneration: two-year efficacy results of the MARINA study. Invest Ophthalmol Vis Sci 47: ARVO E-Abstract 2959.
7. Klein R, Klein BEK, Linton KLP (1992) Prevalence of age related maculopathy: the Beaver Dam Eye Study. Ophthalmology 99: 933-943.
8. Korotkin A, Kozak I, Morrison VL et al (2006): An emerging problem: recurrence of CNV in AMD is common after cessation of 24 month treatment with ranibizumab (Lucentis®). Invest Ophthalmol Vis Sci 47: ARVO E-Abstract 2961.
9. Miller JW, Shapiro H, Acharya N et al (2006): Randomized, controlled phase iii study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age-related macular degeneration: two-year safety results of the MARINA study. Invest Ophthalmol Vis Sci 47: ARVO E-Abstract 3539.
10. Nowak JZ (2006) Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep 58(3): 353-363.
11. Prautzsch J (2008) Neue Daten für eine individualisierte AMD-Therapie: Status Quo und Perspektiven von Ranibizumab in der Ophthalmochirurgie. Z prakt Augenheilkd 29(Suppl 8): 1-4.
12. Rosenfeld PJ, Fung AE, Lalwan GA (2006) Visual acuity outcomes following a variable-dosing regimen for ranibizumab (Lucentis®) in neovascular AMD: the PrONTO study. Invest Ophthalmol Vis Sci 47: ARVO E-Abstract 2958.
13. Schrader WF (2006) Altersbedingte Makuladegeneration: sozioökonomische Zeitbombe in der alternden Gesellschaft. Ophthalmologe 103: 742-748.
14. Vingerling JR, Dielemans I, Hofman A et al (1995) The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 102: 205-210.